Treating aging and its consequences will be a colossal market. The first seeds of the coming boom have already been planted.

Lilly (LLY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Here we discuss three drugmakers, Eli Lilly and Company (LLY), Pfizer (PFE) and AbbVie (ABBV), following their increase in sales and earnings guidance for 2024.

For U.S. stocks, quarterly earnings seasons are set up to follow an old “beat-and-raise” pattern, which can lift share prices. A look ahead at earnings estimates for 2025 highlights a group of companies whose earnings estimates have been raised the most.

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

A large majority of the companies have already reported second-quarter results. While we can call it a mixed earnings season, there are a few companies that beat expectations and reported record revenue and profits.

Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Eli Lilly stock (NYSE: LLY) recently reported its Q2 results, with revenues and earnings exceeding the street expectations. The pharmaceutical giant reported sales of $11.3 billion and adjusted earnings of $3.92 per share, compared to the consensus estimates of $9.9 billion and $2.60, respectively.

Lilly Seaport Innovation Center (LSC) serves as the central hub for Lilly's genetic medicines efforts and houses the first East Coast Lilly Gateway Labs New 346,000 square foot facility will accommodate approximately 500 Lilly scientists and researchers, in addition to 200 people from Lilly Gateway Labs' companies INDIANAPOLIS , Aug. 13, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the opening of the Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport dedicated to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration and chronic pain. "The opening of LSC expands upon Lilly's long-standing presence in the Boston area," said Daniel Skovronsky, M.D.

Eli Lilly claims that it's finally producing enough of its weight loss drugs. Companies producing substitutes for those drugs may have trouble growing soon.

Lilly's Mounjaro and Zepbound are only warming up. The company has several other promising drugs in its lineup and pipeline.

As one of the largest pharmaceutical companies, Eli Lilly (LLY) said its growth trajectory accelerated during Q2 as its medicines are reaching more people worldwide.